Track Gufic Biosciences Ltd.'s current share price, historical price chart, 52-week high/low, and performance across different time periods.
1 Week returns: -2.54 %
Low
376.8
High
418.2
1 Month returns: -10.53 %
Low
376.8
High
452.0
1 Year returns: 13.68 %
Low
267.5
High
467.8
3 Year CAGR: 15.61 %
Low
237.4
High
504.3
5 Year CAGR: 16.31 %
Low
171.8
High
504.3
Note: Prices may be delayed by a few minutes. For historical calculations, prices are adjusted for splits, bonus and rights issue. Percentage change shown is absolute irrespective of the period.
Multi-year trends for Gufic Biosciences Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.
Gufic Biosciences Ltd. Shareholding Pattern
Quarterly breakdown of Gufic Biosciences Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.
Bulk, Block and Insider Trades
Recent bulk deals, block deals, and insider trading activity in Gufic Biosciences Ltd. shares as reported to NSE and BSE.
Frequently Asked Questions
What is the current share price of Gufic Biosciences Ltd.?
The current share price of Gufic Biosciences Ltd. is ₹ 391.80 as of 23 Oct 2026.
What is the market capitalisation of Gufic Biosciences Ltd.?
The market capitalisation of Gufic Biosciences Ltd. stands at ₹ 3,929.09 Cr.
What is the PE ratio of Gufic Biosciences Ltd.?
The Price-to-Earnings (PE) ratio of Gufic Biosciences Ltd. is 53.49 as of the latest trailing twelve months data.
What is the ROE and ROCE of Gufic Biosciences Ltd.?
Gufic Biosciences Ltd. has a Return on Equity (ROE) of 10.14% and a Return on Capital Employed (ROCE) of 12.01% as per the latest financial reports.
What is the 52-week high and low of Gufic Biosciences Ltd.?
The 52-week high of Gufic Biosciences Ltd. is - and the 52-week low is -.
What is the dividend yield of Gufic Biosciences Ltd.?
The dividend yield of Gufic Biosciences Ltd. is 0.03% based on the current market price.
What is the FII and DII holding in Gufic Biosciences Ltd.?
Foreign Institutional Investors (FII) hold 0.44%, Domestic Institutional Investors (DII) hold 3.03% and retail/public investors hold 20.57% of Gufic Biosciences Ltd. shares.
What sector does Gufic Biosciences Ltd. belong to?
Gufic Biosciences Ltd. operates in the Healthcare sector.
What is the beta of Gufic Biosciences Ltd.?
The beta of Gufic Biosciences Ltd. is 0.63, indicating its price volatility relative to the broader market. Over the past 1 year, Gufic Biosciences Ltd. has delivered an absolute return of 7.98%.
What is the RSI of Gufic Biosciences Ltd.?
The 14-day Relative Strength Index (RSI) of Gufic Biosciences Ltd. is 37.91, placing it approaching oversold territory. An RSI above 70 is considered overbought and below 30 is considered oversold.
391.80-2.2 (-0.56%) D
13.68% in past 1 year
Stock Analysis
Fundamental analysis overview of Gufic Biosciences Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.
Views
Red Flags
Positive
Strong price momentum
Price Momentum score of 89.8 indicates that the stock has strong price momentum. Research has shown that stocks with higher momentum continue to outperform in the near term
What is Price Momentum score?
89.8 / 100
Consistently pays dividend
The company has not missed dividend payments once in the last 3 financial years
What is Dividend streak?
Negative
Expensive and at a premium to industry median P/E
PE TTM of 53.49 indicates that the stock is expensive on a standalone basis and is at a 75.55% premium to industry median P/E
What is P/E Ratio?
Median: 30.47
Value 53.49
-0.82614.73
Low dividend yield
The company has a low dividend yield of 0.03%
What is Dividend yield?
Neutral
Company's earnings are of moderate quality
Earnings quality score of 47.4 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion
What is Earnings quality score?
47.4 / 100
No red flags found!
No significant red flags found in the stock.
Net Revenue FY
Profit After Tax FY
ROE FY
EBITDA FY
Mar 2020
Jun 2020
Sep 2020
Dec 2020
Mar 2021
Jun 2021
Sep 2021
Dec 2021
Mar 2022
Jun 2022
Sep 2022
Dec 2022
Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Total Promoter
65.75
65.75
65.75
65.75
65.75
65.13
75.48
75.48
75.48
75.00
75.00
75.00
75.00
75.00
75.00
72.51
72.51
72.50
72.51
72.51
72.51
72.52
72.50
72.50
72.50
72.50
72.50
Indian Promoter
65.75
65.75
65.75
65.75
65.75
65.13
75.48
75.48
75.48
75.00
75.00
75.00
75.00
75.00
75.00
72.51
72.51
72.50
72.51
72.51
72.51
72.52
72.50
72.50
72.50
72.50
72.50
Foreign Promoter
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Institutions
9.52
8.58
8.79
9.04
8.47
3.38
3.65
2.88
2.63
2.51
1.22
1.32
1.88
1.86
2.36
2.20
2.32
2.61
2.74
3.28
3.70
3.70
3.99
4.18
4.25
4.14
3.83
Mutual Funds / UTI
7.80
7.91
8.72
8.70
8.24
3.24
2.13
1.19
1.03
1.03
1.03
1.03
1.03
1.03
1.50
1.60
2.08
2.30
2.51
2.92
3.39
3.38
3.48
3.53
3.63
3.43
3.03
FI/Bank/Insurance
0.08
0.08
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Govt
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
FII
0.59
0.59
0.06
0.33
0.23
0.14
1.52
1.69
1.51
1.38
0.06
0.16
0.72
0.70
0.72
0.47
0.12
0.23
0.23
0.30
0.31
0.32
0.33
0.44
0.42
0.47
0.44
Other Institutions
1.04
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.09
0.10
0.13
0.13
0.13
0.13
0.14
0.12
0.12
0.08
0.00
0.07
0.00
0.00
0.18
0.21
0.20
0.24
0.35
Non-Institution
24.73
25.67
25.46
25.21
25.77
31.49
20.87
21.64
21.89
22.49
23.78
23.69
23.12
23.14
22.64
25.29
25.18
24.88
24.74
24.21
23.79
23.78
23.51
23.32
23.25
23.36
23.67
Bodies Corporate
2.77
2.89
1.72
2.20
2.05
1.41
1.47
0.92
0.90
1.32
1.36
1.27
1.10
1.09
1.41
4.50
4.49
4.73
4.96
4.97
4.91
4.92
1.99
2.18
2.30
2.31
3.10
Others (incl. Retail)
No. of shareholders
21.96
15,376
22.78
16,376
23.74
20,129
23.01
17,982
23.72
19,494
30.08
43,689
19.40
34,943
20.72
34,374
20.99
37,938
21.17
39,887
22.42
41,148
22.42
40,326
22.02
38,674
22.05
38,405
21.23
36,331
20.79
34,201
20.69
34,478
20.15
32,030
19.78
32,597
19.24
33,075
18.88
31,627
18.86
31,670
21.52
31,220
21.14
30,164
20.95
29,035
21.05
29,555
20.57
29,498
Name
Month
Transaction
Holding % pre transaction
Average price
Qty.
Transaction value
JAYESH CHOKSI
Promoter & Director
June-2022
Market Sale (Disposal)
3rd Jun 2022
25.49 %
₹ 220.43
18.00 k
₹ 39.68 lac
JAYESH CHOKSI
Promoter & Director
June-2022
Market Sale (Disposal)
3rd Jun 2022
25.95 %
₹ 217.65
4.50 lac
₹ 9.79 cr
Corporate Actions
History of Gufic Biosciences Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.
Dividend₹ 0.10/share
Record date: 28th Aug 2026Ex-date: 28th Aug 2026
Announced on: 30th May 2026
Dividend₹ 0.10/share
Record date: 22nd Sep 2025Ex-date: 22nd Sep 2025
Announced on: 30th May 2025
Dividend₹ 0.10/share
Record date: 18th Sep 2024Ex-date: 17th Sep 2024
Announced on: 29th May 2024
Dividend₹ 0.10/share
Record date: 21st Sep 2023Ex-date: 21st Sep 2023
Announced on: 29th May 2023
Dividend₹ 0.10/share
Record date: 25th Aug 2022Ex-date: 24th Aug 2022
Announced on: 20th May 2022
Company Profile
Overview of Gufic Biosciences Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.
Gufic Biosciences Limited is an India-based company, which is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services. The Company operates in the pharmaceutical segment. It has pharmaceutical products under categories, such as Criti Care, including Doxific, Micafung, Rabol and Tigefic-Plus; Criticare Life, including Ticofic-200 and Gufivan-500; Ferticare, including Puregraf 75IU 3D, Cetrocare 0.25mg 3D and Follicare 150IU 3D; Spark, including Aznee Duo, Eclin, Flabone, Vipro M and Zad G; Herbal, including Bocomo-Forte, Sallaki-Liniment, Zulcer Cap and Smashit tablet, and Aesthaderm, including Prosil, Moiseta Face Wash and Revanox Serum. Its personal care products include StretchNil, Shapers-Natural Feel, Shaper-DryFeel and RollOn. Its products under active pharmaceutical ingredient (API)/bulk drugs include Micafungin, Anidulafungin, Sulconazole and Everolimus. Its Gufic Stridden includes Irvical and Eve.
Gufic Biosciences Limited is an India-based company, which is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services. The Company operates in the pharmaceutical segment. It has pharmaceutical products under categories, such as Cr...
Key personnel
Mr. Devkinandan B. Roonghta
Chief Financial Officer
Ms. Ami Naresh Shah
Compliance Officer, Company Secretary
Mr. Jayesh P. ChoksiD
Executive Chairman of the Board, Managing Director